Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr;17(4):420-5.
doi: 10.1038/ejhg.2008.188. Epub 2008 Oct 15.

Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome

Affiliations

Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome

Thomas E Neumann et al. Eur J Hum Genet. 2009 Apr.

Abstract

Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFCS) are related developmental disorders caused by mutations in genes encoding various components of the RAS-MAPK signaling cascade. NS is associated with mutations in the genes PTPN11, SOS1, RAF1, or KRAS, whereas CFCS can be caused by mutations in BRAF, MEK1, MEK2, or KRAS. The NS phenotype is rarely accompanied by multiple giant cell lesions (MGCL) of the jaw (Noonan-like/MGCL syndrome (NL/MGCLS)). PTPN11 mutations are the only genetic abnormalities reported so far in some patients with NL/MGCLS and in one individual with LEOPARD syndrome and MGCL. In a cohort of 75 NS patients previously tested negative for mutations in PTPN11 and KRAS, we detected SOS1 mutations in 11 individuals, four of whom had MGCL. To explore further the relevance of aberrant RAS-MAPK signaling in syndromic MGCL, we analyzed the established genes causing CFCS in three subjects with MGCL associated with a phenotype fitting CFCS. Mutations in BRAF or MEK1 were identified in these patients. All mutations detected in these seven patients with syndromic MGCL had previously been described in NS or CFCS without apparent MGCL. This study demonstrates that MGCL may occur in NS and CFCS with various underlying genetic alterations and no obvious genotype-phenotype correlation. This suggests that dysregulation of the RAS-MAPK pathway represents the common and basic molecular event predisposing to giant cell lesion formation in patients with NS and CFCS rather than specific mutation effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical features in patients with syndromic MGCLS. Severe involvement of the jaws resembling cherubism is present in patients 1 (a), 4 (c), and 5 (e). The second also shows severe scoliosis (c). Milder expression in patients 2 (b) and 7 (d). Development of the facial shape in patient 5 (e). (Patient are numbered according to Table 2.)
Figure 2
Figure 2
(a) The radiographs of patients 1 and 4 show bilateral extensive radiolucent lesions in the posterior mandible. (b) The histology pictures of patient 7 show multinucleated giant cells within a fibrous stroma. (HE stain, × 100 and × 400 original magnification. Patients are numbered according to Table 2.)

Similar articles

Cited by

References

    1. Noonan JA. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child. 1968;116:373–380. - PubMed
    1. Allanson JE. Noonan syndrome. J Med Genet. 1987;24:9–13. - PMC - PubMed
    1. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29:465–468. - PubMed
    1. Roberts AE, Araki T, Swanson KD, et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet. 2007;39:70–74. - PubMed
    1. Tartaglia M, Pennacchio LA, Zhao C, et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet. 2007;39:75–79. - PubMed

Publication types

MeSH terms